Siam Bioscience
Native name | สยามไบโอไซเอนซ์ |
|---|---|
| Company type | Private |
| Industry | |
| Founded | 17 August 2009 |
| Founder | Bhumibol Adulyadej |
Key people |
|
| Revenue | |
| Owner | Vajiralongkorn |
Number of employees | 125 (2012) |
| Subsidiaries | Inno Biocosmed |
| Website | siambioscience.com |
Siam Bioscience Company, Ltd. (Thai: สยามไบโอไซเอนซ์) is a Thai drug manufacturer, owned by King Maha Vajiralongkorn.
In 2009, the project started with a partnership between CPB Equity, subsidiary of Crown Property Bureau in the reign of King Bhumibol Adulyadej, and a medical human resource and pharmaceutical technology supporter's Mahidol University. Investing around 2,000 million baht, the project proposes were bio-pharmaceutical product research and producing Thai drugs to reduce the dependence on imported drugs.
The first chair of the board and the key man driving the project was Sanoh Unakul, one of Siam Cement Group's directors. Apiporn Pasawat, former managing director of SCG Chemical, and Songpon Deechongkit, have been CEO and managing director from the beginning.
In 2012, Thailand Board of Investment subsidized Siam Bioscience for 427.50 million baht.